Latest ENLV news and sentiment

Enlivex Ltd. SEC Filing (Aug 14, 2026)

This article reports on an SEC filing by Enlivex Ltd. (NASDAQ: ENLV) on August 14, 2026, which was a Notice of Effectiveness for an F-3 form. The filing was accepted by the SEC EDGAR system on the same day. The article also provides an overview of Enlivex Ltd.'s recent news and SEC filings.

Enlivex Ltd. (ENLV) sees 9.99% stake reported via convertible note

Lind Global Asset Management XIV, LLC, The Lind Partners, LLC, and Jeff Easton have reported beneficial ownership of 9.99% of Enlivex Ltd.'s ordinary shares through a Senior Secured Convertible Promissory Note. The note includes a clause preventing conversion that would lead to ownership exceeding 9.99% of Enlivex's ordinary shares. Each reporting entity holds sole voting and dispositive power over 1,927,744 shares, representing this 9.99% stake.

Enlivex (ENLV) revises $21M secured convertible note, adds 10% interest trigger

Enlivex Ltd. has amended its $21.0 million secured convertible promissory note with Lind Global Asset Management XIV, LLC. The amendment removes a market capitalization-related event of default and waives a previous default, while increasing the outstanding principal from $16.3 million to $19.2 million. A new provision adds a 10.0% annual interest rate if the company's market capitalization falls below $75.0 million.

Enlivex Ltd. (NASDAQ: ENLV) files to register 10M shares for noteholder resale

Enlivex Ltd. (NASDAQ: ENLV) has filed a Form F-3 to register up to 10,000,000 ordinary shares for resale by Lind Global Asset Management XIV, LLC. These shares are related to a previously issued Senior Secured Convertible Promissory Note worth $21.0 million, for which Enlivex received $19.0 million. Enlivex will not receive any proceeds from the resale of these shares but will cover the registration expenses, and as of August 5, 2026, the company had 17,485,462 ordinary shares outstanding, trading at $2.18 per share.

Enlivex Is Maintained at Buy by HC Wainwright & Co.

HC Wainwright & Co. has reiterated its Buy rating on Enlivex Therapeutics Ltd. The article does not provide further details on the reasons behind the rating or any specific price targets.

Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Enlivex Therapeutics Ltd (ENLV), detailing its support and resistance levels, various technical indicators, and moving averages. It highlights the stock's current price momentum, ranking within the Biotechnology & Medical Research industry, and offers a neutral signal based on the combined analysis of its indicators and moving averages. The analysis is presented for reference, with a disclaimer about the accuracy and the non-provision of financial advice.

Enlivex (Nasdaq: ENLV) Rain protocol volume hits $860M, up 622%

Enlivex (Nasdaq: ENLV) announced that trading volume on its Rain protocol reached $860 million as of July 29, 2026, marking a 622% month-over-month increase. The company's digital asset treasury strategy, powered by this protocol, anticipates significant growth, with target trading volumes projected to reach $33 billion by 2029 and associated net fees for token buy-and-burn potentially hitting $600 million. Enlivex combines its longevity therapeutics development with exposure to the emerging prediction markets ecosystem.

Enlivex Therapeutics Ltd (ENLV) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Enlivex Therapeutics Ltd (ENLV), stating its current valuation score as 9.94, ranking 5th in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 0.08, noting its position relative to recent highs and lows. The article also indicates that relevant data for P/B and P/CF ratios have not yet been disclosed by the company.

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

Enlivex Ltd. announced its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time. The webinar will provide investors with details on the company's recent private placement, the status and strategy of its RAIN treasury, and clinical progress for Allocetra™, including its new RMAT designation from the FDA for age-related knee osteoarthritis.

Enlivex (Nasdaq ENLV) to host webinar on capital strategy and RMAT Allocetra

Enlivex Ltd. (Nasdaq: ENLV) will host a live investor webinar on July 30, 2026, at 10:00 AM Eastern Time to discuss its recent private placement, the strategy of its RAIN protocol-based treasury, and clinical progress for its Allocetra™ immunotherapy program. The webinar will also cover the Regenerative Medicine Advanced Therapy (RMAT) designation recently granted by the U.S. FDA to Allocetra™ for age-related knee osteoarthritis in patients aged 64 and older. The company emphasizes its dual strategy of developing longevity therapeutics and operating a prediction markets treasury.

Enlivex Announces $400,000,000 Private Placement

Enlivex Therapeutics Ltd. announced a private placement of $400 million, led by institutional investors. The financing is expected to support the company's clinical development programs and general corporate purposes. This significant investment highlights investor confidence in Enlivex's therapeutic approach.

Enlivex (NASDAQ: ENLV) sets $400M Rain deal and $400M equity put

Enlivex Ltd. has entered into a private placement agreement with the Rain Foundation for up to $400 million in ordinary shares or pre-funded warrants, with an additional discretionary put option for Enlivex to require Rain to purchase up to another $400 million in equity securities. The transaction is subject to shareholder approval under Israeli law and Nasdaq rules. Proceeds from the placement are intended to support Enlivex's digital asset treasury strategy, acquire RAIN tokens, cover transaction costs, and repay indebtedness.

Enlivex (Nasdaq: ENLV) sets $400M RAIN token-linked private placement

Enlivex Ltd. has announced a $400 million private placement with a single institutional investor, involving the issuance of ordinary shares at premiums of 17.4% to 40.8% over the July 27, 2026 closing price, depending on the funding method. The investor currently plans to fund the purchase using RAIN tokens. The proceeds will support Enlivex's prediction markets treasury strategy built around the Rain protocol and advance its Allocetra™ immunotherapy program, with the deal subject to shareholder approval.

Enlivex investor may fund proposed $400M deal with RAIN tokens

Enlivex (Nasdaq: ENLV) has entered into a securities purchase agreement for a private placement of approximately $400 million in ordinary shares or equivalents with a single institutional investor. The investor has currently elected to fund the purchase using RAIN tokens, which offers a higher share price ($6.00 vs. $5.00 for USD/USDT/USDC). The deal, awaiting shareholder approval, will support Enlivex's Rain protocol-based treasury strategy and its clinical-stage immunotherapy Allocetra™.

Enlivex investor may fund proposed $400M deal with RAIN tokens

Enlivex (Nasdaq: ENLV) has entered into a securities purchase agreement for a private placement of approximately $400 million in ordinary shares or equivalents with a single institutional investor. The investor has currently elected to fund the purchase using RAIN tokens, which offers a higher share price ($6.00 vs. $5.00 for USD/USDT/USDC). The deal, awaiting shareholder approval, will support Enlivex's Rain protocol-based treasury strategy and its clinical-stage immunotherapy Allocetra™.

ENLV|Enlivex Therapeutics Ltd|Price:4.250|Chg%:+0.050

Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Enlivex Therapeutics Ltd (ENLV), detailing its support and resistance levels, various technical indicators, and moving averages. It highlights the stock's current price momentum, ranking within the Biotechnology & Medical Research industry, and offers a neutral signal based on the combined analysis of its indicators and moving averages. The analysis is presented for reference, with a disclaimer about the accuracy and the non-provision of financial advice.

Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides a historical overview of dividends and stock splits for Enlivex Therapeutics Ltd (ENLV). It indicates that ENLV has distributed no dividends over the past five years and lists one stock split event: a 15-to-1 merger on July 7, 2026. The stock's current market cap is $67.26M, with a P/E TTM of 0.16.

Enlivex Therapeutics Ltd (ENLV) Balance Sheet

This article presents the annual and quarterly balance sheets for Enlivex Therapeutics Ltd (ENLV), allowing users to evaluate the company's financial health, fundamentals, and key ratios. It includes detailed financial data from FY2015Q1 to FY2025Q4 across assets, liabilities, and shareholders' equity. The document also provides FAQs addressing important balance sheet metrics, definitions of assets, liabilities, and equity, and the distinction between current and non-current items, alongside specific figures for ENLV's cash, total liabilities, total assets, and shareholders' equity.

Enlivex Therapeutics Ltd (ENLV) Income Statement

This article provides the quarterly and annual income statements for Enlivex Therapeutics Ltd (ENLV), offering financial data from Q1 2014 to Q4 2025. It details various financial metrics including revenue, operating expenses, R&D expenses, operating profit, and net income. The page also includes FAQs on how to interpret the income statement, distinguishing between quarterly and annual reports, and defining key terms like YOY.

Enlivex Therapeutics Ltd (ENLV) Cash Flow

This article provides a detailed historical cash flow statement for Enlivex Therapeutics Ltd (ENLV), breaking down operating, investing, and financing activities from FY2015Q1 to FY2025Q4. It includes key financial metrics like net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. The piece also offers definitions and explanations of cash flow components to aid in financial analysis of the company.

Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Enlivex Therapeutics Ltd (ENLV). It indicates that relevant data for business segments and regional revenue and profit contribution have not yet been disclosed by the company. The page also presents basic financial information like market cap and P/E ratio.

Enlivex Therapeutics Ltd (ENLV) Institutional Confidence

The article provides a snapshot of Enlivex Therapeutics Ltd (ENLV) focusing on its institutional confidence score as part of TradingKey's stock analysis. As of July 24, 2026, the company has a market capitalization of $66.47 million and a P/E TTM of 0.16. The institutional confidence score remains at 3.00, indicating no change from its previous score.